Spots Global Cancer Trial Database for acute myelogenous leukemia
Every month we try and update this database with for acute myelogenous leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML) | NCT00486265 | Acute Myelogeno... | AZD4877 | 18 Years - | AstraZeneca | |
| Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | NCT00334074 | Acute Myelogeno... Myelodysplastic... Chronic Myeloge... | Clofarabine and... | 18 Years - 85 Years | Baylor Research Institute | |
| Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome | NCT01795924 | Acute Myelogeno... Myelodysplastic... | PD-616 | 18 Years - 75 Years | Biosuccess Biotech Co., Ltd. | |
| AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS | NCT00396968 | Acute Myelogeno... Myelodysplastic... | AMD3100 Allogeneic Stem... | 18 Years - 60 Years | Sanofi | |
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | NCT02639559 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Non-Hodgkin's L... Non-Hodgkin Lym... Hodgkin Disease Hodgkins Diseas... Hodgkin's Disea... Multiple Myelom... Myelodysplastic... Myeloproliferat... | BL-8040 Leukapheresis Hematopoietic c... | 18 Years - 75 Years | Washington University School of Medicine | |
| Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia | NCT00136422 | Acute Myelogeno... Myelodysplasia | autologous tumo... | 18 Years - | Dana-Farber Cancer Institute | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| WT1 for the Detection of Minimal Residual Disease | NCT00179829 | Leukemia Cancer | WT 1 Testing | - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia | NCT04172844 | Acute Myelogeno... | Azacitidine Venetoclax Pevonedistat | 18 Years - | Medical College of Wisconsin | |
| Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies | NCT00270881 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... | Cord blood tran... TBI cyclophosphamid... cytarabine | 20 Years - 55 Years | Keio University | |
| Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) | NCT01385423 | Acute Myelogeno... Myelodysplastic... | Preparative Reg... Intravenous Rec... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | NCT00720850 | Myelodysplastic... Acute Myelogeno... | lenalidomide | 18 Years - | Technische Universität Dresden | |
| Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. | NCT02017457 | Acute Myelogeno... Myelodysplastic... | Donor lymphocyt... Azacytidine | 18 Years - | University Hospital of Mont-Godinne | |
| AHN-12 Biodistribution in Advanced Leukemia | NCT01207076 | Acute Myelogeno... Myelodysplastic... Acute Lymphobla... Chronic Myeloge... | 90Y-AHN-12 | 12 Years - | Masonic Cancer Center, University of Minnesota | |
| Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | NCT00948064 | Leukemia | Vorinostat Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00090727 | Solid Malignanc... Non-Hodgkin's L... | AQ4N | 18 Years - | Novacea | |
| Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) | NCT00074750 | Acute Myelogeno... Chronic Myelomo... | DTGM | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT00136461 | Acute Myelogeno... Myelodysplastic... | All-trans retin... Bryostatin 1 | 18 Years - | Dana-Farber Cancer Institute | |
| Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia | NCT01736943 | Acute Myelogeno... | Bortezomib Doxil | 18 Years - 80 Years | University of California, Davis | |
| Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) | NCT02203773 | Acute Myelogeno... Myelogenous Leu... Treatment Naive... | Posaconazole ABT-199 Decitabine Azacitidine | 60 Years - | AbbVie | |
| Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) | NCT00686543 | Fungal Infectio... Acute Myelogeno... Neutropenia | Posaconazole | 18 Years - | Merck Sharp & Dohme LLC | |
| Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations | NCT00943943 | Acute Myelogeno... Leukemia | G-CSF Plerixafor Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Biology Studies of Hematologic Cancers | NCT00923442 | Acute Lymphobla... Myelodysplastic... Non-Hodgkins Ly... Acute Myelogeno... Hodgkins Lympho... | 1 Year - 75 Years | National Institutes of Health Clinical Center (CC) | ||
| Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM) | NCT01146262 | Acute Myelogeno... | cell therapy pr... injection of th... | 60 Years - | Nantes University Hospital | |
| Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer | NCT00005785 | Hematologic Neo... HIV Infection | GCSF Mobilized ... | - | National Institutes of Health Clinical Center (CC) | |
| Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant | NCT00571662 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Chronic Lymphoc... Myelodysplastic... Multiple Myelom... Non-Hodgkins Ly... Hodgkins Diseas... Peripheral T-ce... | Pentostatin Total-body irra... Cyclosporine A ... Mycophenolate M... G-CSF | 19 Years - 75 Years | University of Nebraska | |
| Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow | NCT00003838 | Myeloproliferat... Acute Myelogeno... Chronic Myeloge... Myelodysplastic... Acute Lymphobla... | T-cell replete ... Methotrexate Cyclosporine G-CSF | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome | NCT05263271 | Acute Myelogeno... Myelodysplastic... | Gentulizumab | 18 Years - 75 Years | Changchun GeneScience Pharmaceutical Co., Ltd. | |
| Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia | NCT02113319 | Acute Myelogeno... | dasatinib | 18 Years - 60 Years | University Hospital, Angers | |
| Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML) | NCT00398983 | Acute Myelogeno... | Decitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients | NCT02109744 | Acute Myelogeno... | Decitabine | 18 Years - 70 Years | University of Rochester | |
| Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant | NCT01244906 | Hematologic Neo... | Allogeneic Hema... | 18 Years - 75 Years | Northside Hospital, Inc. | |
| Epigenetic Reprogramming in Relapse/Refractory AML | NCT03263936 | Acute Myelogeno... | Decitabine Vorinostat Filgrastim (G-C... Fludarabine Cytarabine | 1 Year - 25 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Molecular Epidemiology of Acute Myelogenous Leukemia | NCT00502983 | Leukemia | Interview | 18 Years - | M.D. Anderson Cancer Center | |
| An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia | NCT00171249 | Philadelphia Po... Acute Lymphobla... Acute Myeloid L... | STI571 400 mg STI571 600 mg | 18 Years - | Novartis | |
| A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor | NCT01696461 | Related Donors ... Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Non-Hodgkin's L... Hodgkin's Disea... Chronic Lymphoc... | Plerixafor | 18 Years - 65 Years | Center for International Blood and Marrow Transplant Research | |
| A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) | NCT00317642 | Acute Myelogeno... | clofarabine (IV... placebo cytarabine | 55 Years - | Sanofi | |
| Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia | NCT00044889 | Acute Myelogeno... | clofarabine (IV... | 18 Years - | Sanofi | |
| Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML) | NCT01160354 | Acute Myelogeno... | Plerixafor Clofarabine | 60 Years - | M.D. Anderson Cancer Center | |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | NCT02593123 | Hodgkin's Lymph... Lymphoid Leukem... Lymphoma Leukemia Myeloma Acute Lymphocyt... Non Hodgkin Lym... Chronic Lymphoc... Multiple Myelom... Chronic Myeloge... Myelodysplastic... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Recurrent Plasm... Recurrent Chron... Recurrent Chron... Acute Myelogeno... | mycophenolate m... Sargramostim Filgrastim | 18 Years - 74 Years | Virginia Commonwealth University | |
| Cancer Experience Registry (CER) for Cancer Patients and Caregivers | NCT02333604 | Neoplasms Cancer Caregiver | 18 Years - | Cancer Support Community, Research and Training Institute, Philadelphia | ||
| Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | NCT00334074 | Acute Myelogeno... Myelodysplastic... Chronic Myeloge... | Clofarabine and... | 18 Years - 85 Years | Baylor Research Institute | |
| Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | NCT01019317 | Leukemia AML MDS CML | Cytarabine Fludarabine | 12 Years - | M.D. Anderson Cancer Center | |
| Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy | NCT04014764 | Acute Myelogeno... Multiple Myelom... Myelodysplastic... Lymphoma Acute Lymphobla... Chronic Myeloge... Myeloproliferat... | This is a non-i... | 18 Years - | Notable Labs | |
| Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With Leukemia | NCT01204788 | Leukemia | Prophylactic Wh... Therapeutic Whi... | 2 Years - | M.D. Anderson Cancer Center | |
| Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation | NCT01483274 | Acute Myelogeno... | Vaccine | 18 Years - 75 Years | University of Louisville | |
| Bisantrene for Relapsed /Refractory AML | NCT03820908 | Acute Myelogeno... Allogeneic Stem... | Bisantrene | 18 Years - | Sheba Medical Center | |
| Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) | NCT00406393 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Myelo... Myelodysplastic... | Tacrolimus Methotrexate Sirolimus | 2 Years - 60 Years | Medical College of Wisconsin | |
| TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation | NCT01300611 | Double Cord Blo... Acute Myelogeno... Myelodysplastic... Myelofibrosis Acute Lymphobla... Chronic Myelocy... Non Hodgkins Ly... Hodgkins Lympho... Chronic Lymphoc... | TXA127 300 mcg/... TXA127 1000 mcg... | 18 Years - 60 Years | Tarix Pharmaceuticals | |
| An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia | NCT00171249 | Philadelphia Po... Acute Lymphobla... Acute Myeloid L... | STI571 400 mg STI571 600 mg | 18 Years - | Novartis | |
| A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome | NCT00830518 | Acute Myelogeno... High-Grade Myel... | Alisertib | 18 Years - | Takeda | |
| HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies | NCT01119066 | Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Multiple Myelom... | total body irra... Thiotepa Cyclophosphamid... Busulfan Melphalan Fludarabine Clofarabine (CliniMACS) T-c... | - 69 Years | Memorial Sloan Kettering Cancer Center | |
| Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia | NCT00623935 | Acute Myelogeno... | Fludarabine Busulfan Total Body Irra... Stem Cell Trans... | 55 Years - 70 Years | University of Michigan Rogel Cancer Center | |
| Stem Cell Transplantation for Patients With Cancers of the Blood | NCT00467961 | CML (Chronic My... CLL (Chronic Ly... AML (Acute Myel... Acute Lymphocyt... MDS (Myelodyspl... | Miltenyi system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) | NCT00074750 | Acute Myelogeno... Chronic Myelomo... | DTGM | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell | NCT01660607 | Myeloid Leukemi... Acute Myelogeno... Myelodysplastic... Lymphoma, Non-H... Acute Lymphobla... Myeloproliferat... Acute Myeloid L... Acute Leukemia Chronic Myeloge... | Conventional T ... | 13 Years - 60 Years | Stanford University | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | NCT00760084 | Acute Myelogeno... Myelodysplastic... | Decitabine | 18 Years - | Eisai Inc. | |
| Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies | NCT00270881 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... | Cord blood tran... TBI cyclophosphamid... cytarabine | 20 Years - 55 Years | Keio University | |
| Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML) | NCT00822094 | Acute Myeloid L... | CPX-351 Intensive Salva... | 18 Years - 65 Years | Jazz Pharmaceuticals | |
| A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS | NCT00656448 | Acute Myelogeno... Myelodysplastic... Leukemia | Procrit | - | M.D. Anderson Cancer Center | |
| Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia | NCT01289678 | Acute Myelogeno... | Interleukin-2 | 18 Years - | Leo W. Jenkins Cancer Center | |
| Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia | NCT01513109 | Acute Myelogeno... Myeloid Leukemi... Effects of Immu... | Recombinant WT1... | 18 Years - | Jules Bordet Institute | |
| Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | NCT01634217 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Non-Hodgkin Lym... Hodgkin Lymphom... Chronic Lymphoc... Multiple Myelom... Myelodysplastic... | iTreg | 18 Years - 75 Years | Masonic Cancer Center, University of Minnesota | |
| PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP | NCT00088231 | Acute Myelogeno... Agnogenic Myelo... Chronic Myeloge... | Imatinib Mesyla... PTK 787 (vatala... | 15 Years - | M.D. Anderson Cancer Center | |
| Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes | NCT00981240 | Acute Myelogeno... | SAR103168 | 18 Years - | Sanofi | |
| Cancer Experience Registry (CER) for Cancer Patients and Caregivers | NCT02333604 | Neoplasms Cancer Caregiver | 18 Years - | Cancer Support Community, Research and Training Institute, Philadelphia | ||
| Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia | NCT00136422 | Acute Myelogeno... Myelodysplasia | autologous tumo... | 18 Years - | Dana-Farber Cancer Institute | |
| Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years | NCT01193400 | Acute Myelogeno... | Clofarabine Cytarabine | 60 Years - | PETHEMA Foundation | |
| Brentuximab Vedotin + Re-induction Chemotherapy for AML | NCT01830777 | Acute Myelogeno... | Brentuximab Ved... Mitoxantrone Etoposide Cytarabine | 18 Years - | Massachusetts General Hospital | |
| Low Dose Melphalan and Bortezomib for AML and High-Risk MDS | NCT00789256 | Acute Myelogeno... Myelodysplastic... | Melphalan Bortezomib Melphalan and b... | - | Dartmouth-Hitchcock Medical Center | |
| High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML | NCT00474006 | ACUTE MYELOGENO... | arm II | 15 Years - 60 Years | Cooperative Study Group A for Hematology | |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | NCT00975975 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Chronic Lymphoc... Myelodysplasia Non-Hodgkin's L... Hodgkin's Disea... Multiple Myelom... Myelofibrosis Anemia, Aplasti... Hemoglobinuria,... | Basiliximab | 18 Years - | Indiana University | |
| A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML) | NCT01090167 | Acute Myelogeno... | clofarabine | 20 Years - 74 Years | Sanofi | |
| Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies | NCT02566395 | Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Chronic Myeloge... Non-Hodgkin Lym... Hodgkin Lymphom... | Radiation Cyclophosphamid... Donor Lymphocyt... Haploidentical ... | 2 Years - 21 Years | Northwell Health | |
| T-Cell Depleted Double UCB for Refractory AML | NCT01464359 | Acute Myelogeno... Refractory Acut... | Allopurinol Fludarabine Total body irra... Cyclophosphamid... Levetiracetam Busulfan Umbilical Cord ... Interleukin-2 | 2 Years - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes | NCT00038870 | Acute Myelogeno... Chronic Myeloge... | Dendritic Cell ... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies | NCT01471067 | Blood And Marro... Leukemia Lymphoma Transplantation... Transplantation... | Melphalan Fludarabine Mycophenolate m... Tacrolimus Cord Blood Infu... Rituximab ATG Busulfan Clofarabine Total Body Irra... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia | NCT02665065 | Acute Myeloid L... Leukemia, Acute... Myeloid Leukemi... Leukemia, Myelo... Acute Myelogeno... Leukemia, Acute... Myelogenous Leu... AML Bone Marrow Tra... | Iomab-B Conventional Ca... HCT | 55 Years - | Actinium Pharmaceuticals |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
